Jerzy Jankun

Summary

Affiliation: University of Toledo
Country: USA

Publications

  1. ncbi A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis
    Joanna Chorostowska-Wynimko
    Medical College of Ohio, Urology Research Center, Department of Urology, Toledo, Ohio 43614-5807, USA
    Mol Cancer Ther 2:19-28. 2003
  2. ncbi Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, The Univesrsity of Toledo, Toledo, OH 43614, USA
    Pharmacol Rep 61:673-80. 2009
  3. ncbi Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo Health Science Campus, Toledo, OH 43614, USA
    Int J Mol Med 26:501-4. 2010
  4. ncbi PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells
    Jerzy Jankun
    Urology Research Center, University of Toledo, Health Science Campus, Toledo, OH 43614 5807, USA
    Int J Mol Med 20:11-20. 2007
  5. ncbi VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form
    Jerzy Jankun
    Urology Research Center, University of Toledo, Health Science Campus, 3065 Arlington, Toledo, OH 43614 5807, USA
    Int J Mol Med 23:57-63. 2009
  6. ncbi Yin and yang of the plasminogen activator inhibitor
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, The University of Toledo, Toledo, OH, United States
    Pol Arch Med Wewn 119:410-7. 2009
  7. ncbi Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, The University of Toledo, Toledo, OH 43614, USA
    BJU Int 105:1469-76. 2010
  8. ncbi Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo Health Science Campus, 3000 Arlington Ave, Toledo, OH 43614, USA
    Int J Mol Med 27:525-9. 2011
  9. ncbi Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review)
    Jerzy Jankun
    Department of Urology, Urology Research Center, The University of Toledo, Toledo, OH 43614, USA
    Int J Mol Med 29:3-11. 2012
  10. ncbi Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo, Toledo, OH 43614, USA
    Int J Mol Med 29:61-4. 2012

Research Grants

  1. Computer Directed Photodynamic Therapy of Prostate Ca
    Jerzy Jankun; Fiscal Year: 2005

Collaborators

Detail Information

Publications35

  1. ncbi A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis
    Joanna Chorostowska-Wynimko
    Medical College of Ohio, Urology Research Center, Department of Urology, Toledo, Ohio 43614-5807, USA
    Mol Cancer Ther 2:19-28. 2003
    ..g., in the inhibition of sprout formation. Such prolonged serpin activity, which is therapeutically desired in cancer treatment and Cys-mutated PAI-1, could launch a new class of novel anticancer agents...
  2. ncbi Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, The Univesrsity of Toledo, Toledo, OH 43614, USA
    Pharmacol Rep 61:673-80. 2009
    ....
  3. ncbi Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo Health Science Campus, Toledo, OH 43614, USA
    Int J Mol Med 26:501-4. 2010
    ....
  4. ncbi PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells
    Jerzy Jankun
    Urology Research Center, University of Toledo, Health Science Campus, Toledo, OH 43614 5807, USA
    Int J Mol Med 20:11-20. 2007
    ..We hope that by exploring PAI-1's structure and function we might be able to understand and separate the different effects of PAI-1 on cancer cells and develop more effective therapeutic strategies in cancer treatment...
  5. ncbi VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form
    Jerzy Jankun
    Urology Research Center, University of Toledo, Health Science Campus, 3065 Arlington, Toledo, OH 43614 5807, USA
    Int J Mol Med 23:57-63. 2009
    ..We postulate that the active structures differ in RCL conformation and their position in relation to the gate region and the rest of the molecule...
  6. ncbi Yin and yang of the plasminogen activator inhibitor
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, The University of Toledo, Toledo, OH, United States
    Pol Arch Med Wewn 119:410-7. 2009
    ..Also, a role of PAI-1 in cancer is discussed with attention to "PAI-1 paradox" and explanation of the possible therapeutic applications using this protein...
  7. ncbi Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, The University of Toledo, Toledo, OH 43614, USA
    BJU Int 105:1469-76. 2010
    ..To investigate the potential for the future clinical use of a very long half-life plasminogen activator inhibitor type 1 (VLHL PAI-1) as a haemostatic agent...
  8. ncbi Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo Health Science Campus, 3000 Arlington Ave, Toledo, OH 43614, USA
    Int J Mol Med 27:525-9. 2011
    ..Among four tested theaflavins, theaflavin-3'-gallate was the most potent in PAI-1 inhibition trailed by theaflavin-3,3'-digallate, while the other two i.e., theaflavin and theaflavin-3-gallate did not show inhibitory activity...
  9. ncbi Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review)
    Jerzy Jankun
    Department of Urology, Urology Research Center, The University of Toledo, Toledo, OH 43614, USA
    Int J Mol Med 29:3-11. 2012
    ..Thus inactivating of PAI-1 or increasing its clearance can alleviate the burden of obesity and diabetes...
  10. ncbi Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo, Toledo, OH 43614, USA
    Int J Mol Med 29:61-4. 2012
    ....
  11. ncbi Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis
    Jerzy Jankun
    Urology Research Center, Health Science Campus, University of Toledo, Toledo, OH 43614 5807, USA
    Int J Mol Med 20:683-7. 2007
    ....
  12. ncbi Protein-based nanotechnology: antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy
    Jerzy Jankun
    Urology Research Center, Department of Urology, The University of Toledo Health Science Campus, 3000 Arlington Ave, Toledo, OH 43614, USA
    Int J Oncol 39:949-53. 2011
    ..Our results show clearly that mAb/HP conjugates can deliver HP to the tumor cells which would result in considerably less HP in the circulation and, therefore, lower the delivery of HP to normal tissue, resulting in fewer side effects...
  13. ncbi Val17Ile single nucleotide polymorphisms similarly as Ala15Thr could be related to the lower secretory dynamics of PAI-1 secretion: theoretical evidence
    J Jankun
    Urology Research Center, Department of Urology, The University of Toledo Health Science Campus, OH 43614, USA
    Curr Mol Med 11:512-6. 2011
    ..The Asn195Ile mutant may be more stable only as latent form thus no PAI-1 deficiency is expected in this mutant...
  14. ncbi Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity
    Jerzy Jankun
    Urology Research Center, Medical University of Ohio, Toledo, 43614, USA
    Int J Mol Med 17:437-47. 2006
    ..The polymerization of PAI-1 reduces PAI-1 activity by encapsulating the critical RCL fragment inside the formed PAI-1/PAI-1 polymers...
  15. ncbi Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy
    Jerzy Jankun
    Urology Research Center, Department of Urology, Medical College of Ohio, Toledo, 43614 5807, USA
    J Urol 172:739-43. 2004
    ..Successful treatment requires knowledge of the optical properties of the target tissue, a critical element for therapy...
  16. ncbi Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy
    Jerzy Jankun
    Urology Research Center, Medical College of Ohio, Toledo, OH 43614, USA
    BJU Int 95:1237-44. 2005
    ..To explore the use of photodynamic therapy (PDT) as a minimally invasive form of treatment for organ-confined prostate cancer, for although there are several therapies, ablative treatments are associated with significant morbidity...
  17. ncbi Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity?
    Ewa Skrzypczak-Jankun
    Urology Research Center, Department of Urology, University of Toledo Health Science Campus, Toledo, OH 43614, USA
    Int J Mol Med 26:45-50. 2010
    ..While the clinical value of TH(2) has not been proven, long-term prospective studies assessing its efficacy are warranted due to the benign nature of the substance...
  18. ncbi Human platelet 12-lipoxygenase: naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior
    Ansari M Aleem
    Urology Research Center, College of Medicine, University of Toledo, Toledo, OH 43614, USA
    Int J Mol Med 24:759-64. 2009
    ....
  19. ncbi Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells
    Jerzy Jankun
    Urology Research Center, Medical University of Ohio, 3065 Arlington, Toledo, OH 43614 5807, USA
    Mol Cancer Ther 5:1371-82. 2006
    ..This universal event for all tested lipoxygenase inhibitors suggests that the inhibition of sprout formation was most likely due to the inhibition of human P-12-LOX but not other cancer-related pathways...
  20. ncbi Lipoxygenase interactions with natural flavonoid, quercetin, reveal a complex with protocatechuic acid in its X-ray structure at 2.1 A resolution
    Oleg Y Borbulevych
    Medical College of Ohio, Urology Research Center, Department of Urology, Toledo, Ohio 43614, USA
    Proteins 54:13-9. 2004
    ..These compounds might be vulnerable to the co-oxidase activity of LOX, leading to enzyme-stimulated oxidative degradation, which results in an inhibitor of a lower molecular weight...
  21. ncbi Soybean lipoxygenase-3 in complex with 4-nitrocatechol
    Ewa Skrzypczak-Jankun
    Medical College of Ohio, Urology Research Center, Department of Urology, 3065 Arlington Avenue, Toledo OH 43614, USA
    Acta Crystallogr D Biol Crystallogr 60:613-5. 2004
    ..A description of the catechol binding contributes to the understanding of lipoxygenase inhibition and the participation of its co-oxidative activity in the utilization of natural flavonoids...
  22. ncbi Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 A reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead
    Ewa Skrzypczak-Jankun
    Urology Research Center, Medical College of Ohio, Toledo, OH 43614 5807, USA
    Int J Mol Med 12:415-20. 2003
    ....
  23. ncbi In vivo and in vitro effect of baicalein on human prostate cancer cells
    Ranko Miocinovic
    Urology Research Center, Department of Urology, Medical College of Ohio, Toledo, OH 43614, USA
    Int J Oncol 26:241-6. 2005
    ..01) when compared to the control. This is the first study demonstrating an in vivo growth inhibitory effect of orally administered baicalein on human prostate tumors in mice...
  24. ncbi Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment
    Jerzy Jankun
    Urology Research Center, Medical University of Ohio, Department of Urology, Toledo, OH 43614 5807, USA
    Oncol Rep 16:341-6. 2006
    ..If true, a proper diet rich in uPA-inhibiting nutraceuticals might support the prevention of prostrate cancer and be a supportive tool in prostate cancer treatment...
  25. ncbi Human platelet 12-lipoxygenase, new findings about its activity, membrane binding and low-resolution structure
    Ansari M Aleem
    Urology Research Center, College of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, OH 43614, USA
    J Mol Biol 376:193-209. 2008
    ....
  26. ncbi Structure of curcumin in complex with lipoxygenase and its significance in cancer
    Ewa Skrzypczak-Jankun
    Department of Urology, Urology Research Center, Medical College of Ohio, Toledo, OH 43614 5807, USA
    Int J Mol Med 12:17-24. 2003
    ..Our observations about this radiation and time-dependent inhibition add new information to the role that curcumin might play in cancer prevention and treatment...
  27. ncbi Computer simulation of prostate cryoablation--fast and accurate approximation of the exact solution
    Adam Wojtowicz
    Urology Research Center, Department of Urology, Medical College of Ohio, Toledo, Ohio, USA
    Comput Aided Surg 8:91-7. 2003
    ..CONCLUSION: Changes in the PDE solver algorithm produce more accurate results, leading to an improved visualization of the iceball, with a precision of a few mm and a significant decrease in computation time...
  28. ncbi Do human lipoxygenases have a PDZ regulatory domain?
    Jerzy Jankun
    Urology Research Center, Department of Urology, Health Science Campus, University of Toledo, 3000 Arlington Ave, Toledo, OH 43614, USA
    Curr Mol Med 8:768-73. 2008
    ....
  29. ncbi Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase
    N Patrick McCabe
    Urology Research Center, Medical University of Ohio at Toledo, Toledo, Ohio OH 43699 0008, USA
    Prostate 66:779-87. 2006
    ..The mechanisms underlying the role of P12-LOX in angiogenesis remain unclear...
  30. ncbi Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy
    Jacek Aniola
    Urology Research Center, Medical College of Ohio, Toledo, OH 43614-5807, USA
    Int J Mol Med 11:287-91. 2003
    ..It is clear therefore that any future attempts of computerized modeling of this procedure must take into consideration the uneven sequestration of photosensitizer and the consequential asymmetrical necrosis of the prostate...
  31. ncbi Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer
    Amira Gohara
    Department of Pathology, College of Medicine, University of Toledo, Toledo, OH 43614, USA
    Oncol Rep 28:1275-82. 2012
    ..Thus, it may be valuable to probe 12S-LOX activity and monitor its natural metabolite to seek a possible aid in directing the treatment of patients...
  32. ncbi Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products
    Jerzy Jankun
    Urology Research Center, Department of Urology, College of Medicine, University of Toledo, Toledo, OH 43614, USA
    Int J Mol Med 31:1153-8. 2013
    ..These can further form high molecular weight oxidation products. Thus, metals present in tea could diminish the beneficial effects of black tea by reducing TF concentration via metal-induced degradation and precipitation...
  33. ncbi Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review)
    Joanna Chorostowska-Wynimko
    Department of Laboratory Diagnostics and Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
    Int J Mol Med 13:759-66. 2004
    ..This review summarizes recent findings on the structure and functional activity of the plasminogen activator inhibitor type-1, and current opinions on its role in tumorigenesis...
  34. ncbi Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT
    Lothar Lilge
    Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
    Phys Med Biol 49:3209-25. 2004
    ..84+/-0.36 cm(-1)). Significant spatial and temporal intra- and inter-canine variability in the tissue optical properties was noted, highlighting the need for individualized monitoring of the fluence rate for improved dosimetry...
  35. ncbi Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells
    Joanna Chorostowska-Wynimko
    Department of Laboratory Diagnostics and Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
    Oncol Rep 12:1155-62. 2004
    ..We conclude that while the anti-proteolytic properties of PAI-1 constructs are preserved, these proteins inhibit angiogenesis and inhibitory activity dominates over any stimulatory effects of PAI-1...

Research Grants5

  1. Computer Directed Photodynamic Therapy of Prostate Ca
    Jerzy Jankun; Fiscal Year: 2005
    ....